<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02635386</url>
  </required_header>
  <id_info>
    <org_study_id>RP15-008</org_study_id>
    <secondary_id>AZ ESR-14-10725</secondary_id>
    <nct_id>NCT02635386</nct_id>
  </id_info>
  <brief_title>EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)</brief_title>
  <official_title>Comparison of Dapagliflozin (DAPA) and Once-weekly Exenatide (EQW), Co-administered or Alone, DAPA/ Glucophage (DAPA/MET ER) and Phentermine/Topiramate (PHEN/TPM) ER on Metabolic Profiles and Body Composition in Obese PCOS Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woman's</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Woman's</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single-blind, parallel 5 treatment group 24-week trial designed to&#xD;
      directly compare the therapeutic effects of exenatide once weekly (EQW), dapagliflozin&#xD;
      (DAPA), EQW plus DAPA, combined DAPA/metformin extended release (XR) and the weight loss&#xD;
      medication, phentermine/topiramate extended release (PHEN/TPM ER) on metabolic and&#xD;
      endocrinological parameters in overweight/obese non-diabetic women with PCOS. In this study,&#xD;
      we will examine the efficacy of these therapies on metabolic parameters, body weight and body&#xD;
      composition, anthropometric measurements, and reproductive function in a well-defined group&#xD;
      of pre-menopausal overweight/obese, non-diabetic women with PCOS, focusing on their&#xD;
      relationship to insulin resistance and obesity. We hope to determine which treatment(s)&#xD;
      addressing the multifaceted disturbances of individual subgroups emerge as the preferable&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome is a heterogeneous condition characterized by disordered&#xD;
      reproductive and metabolic function which accounts for the myriad of clinical features&#xD;
      including androgen excess, chronic anovulation, insulin resistance adiposity, and&#xD;
      dyslipidemia. This syndrome is highly prevalent, affecting between 8 and 18% of the female&#xD;
      population, depending on the diagnostic criteria used. Hyperandrogenism, ovarian dysfunction&#xD;
      and metabolic abnormalities - the main determinants of PCOS - all appear to be involved in a&#xD;
      synergistic way in the pathophysiology of PCOS. Women with PCOS are more likely to be obese:&#xD;
      between 38 and 88% of women with PCOS are overweight or obese, although PCOS can also&#xD;
      manifest in lean women. Obesity, particularly abdominal obesity, plays a central role in the&#xD;
      development of PCOS, and exacerbates the reproductive and metabolic dysfunction. Rather than&#xD;
      absolute body weight, it is the distribution of fat that is important with central (visceral)&#xD;
      adiposity being a risk factor. Visceral adipose tissue is more metabolically active than&#xD;
      subcutaneous fat and the amount of visceral fat correlates with insulin resistance and&#xD;
      hyperinsulinemia. Weight gain is also often an important pathogenic factor, with PCOS usually&#xD;
      becoming clinically manifest in women with a presumable genetic predisposition for PCOS who&#xD;
      subsequently gain weight. Therefore, environmental (particularly dietary) factors are&#xD;
      important. However, BMI is also influenced by genetic factors such as the fat mass and&#xD;
      obesity-associated protein, and obesity is a highly heritable condition. Therefore, the&#xD;
      weight gain responsible for the manifestation of PCOS in many women with this condition is&#xD;
      itself influenced by genetic factors. Ethnicity, genetic background, personal and family&#xD;
      history, degree of obesity must all be taken into account because they might aggravate or&#xD;
      even trigger metabolic disturbances women with PCOS. Moreover, the incidence of glucose&#xD;
      intolerance, dyslipidemia, gestational diabetes, and type 2 diabetes (DM2) is increased in&#xD;
      women with PCOS at all weight levels and at a young age. PCOS may be a more important risk&#xD;
      factor than ethnicity or race for glucose intolerance in young women. The exact factors&#xD;
      responsible for this excess risk in women with PCOS have not been identified; family history&#xD;
      of DM 2, obesity, insulin resistance, beta cell (ß-cell) secretory dysfunction, and&#xD;
      hyperandrogenism are possible candidates. With better understanding of its pathophysiology,&#xD;
      the metabolic consequences of the syndrome are now evident. Therefore, these patients need to&#xD;
      be followed up even after their presenting complaint has been adequately resolved.&#xD;
&#xD;
      Lifestyle modification is a key component for the improvement of reproductive function for&#xD;
      overweight, anovulatory women with PCOS. Even a modest weight loss 5% of total body weight&#xD;
      can restore ovulation in overweight women with PCOS. Features of PCOS (e.g., hirsutism,&#xD;
      testosterone levels, insulin resistance, menstrual cyclicity and ovulation) showed marked&#xD;
      improvements, and PCOS frequently resolved after substantial weight loss induced by bariatric&#xD;
      surgery. Recently a number of anti-diabetes medications have been approved which facilitate&#xD;
      weight loss and improve the underlying insulin resistance. We reported that treatment with&#xD;
      the glucagon like peptide -1 (GLP-1) agonist, exenatide for 24 weeks was superior to single&#xD;
      agent metformin treatment in improving insulin action and reducing body weight and&#xD;
      hyperandrogenism in obese women with PCOS. We further observed exenatide treatment&#xD;
      significantly improved first-phase insulin responses to oral glucose administration. Since&#xD;
      aberrant first-phase insulin secretion and impaired suppression of endogenous glucose&#xD;
      production are major contributors to postprandial hyperglycemia and development of type 2&#xD;
      diabetes, the effects of exenatide once weekly [EQW (2 mg)] to target these defects, and&#xD;
      normalize glucose excursions are likely to be clinically significant in obese patients with&#xD;
      PCOS. Sodium/glucose cotransporter 2 (SGLT-2) inhibitors are the newest class of medications&#xD;
      for diabetes management that have not been investigated for use in the women with PCOS. The&#xD;
      SGLT2 inhibitor, dapagliflozin [DAPA (10 mg/day)] has an insulin-independent action, promotes&#xD;
      weight loss, has a low incidence of hypoglycemia, and complements the action of other&#xD;
      antidiabetic agents. The loss of glucose with attendant caloric loss contributes to weight&#xD;
      loss; in addition, improvements in β cell function have been seen. Because the SGLT2&#xD;
      inhibitors have a distinct mechanism of action that is independent of insulin secretion, the&#xD;
      efficacy of this class of drugs is not anticipated to decline in the presence of severe&#xD;
      insulin resistance. The weight loss seen with SGLT2 inhibitors is similar to that seen with&#xD;
      glucagon-like peptide 1 agonists, and may be more acceptable because they are oral agents.&#xD;
      The resulting weight loss will further assist in decreasing insulin resistance, leading to&#xD;
      increased glucose disposal thus contributing to an increased insulin secretion-insulin&#xD;
      sensitivity (ISSI) index, the primary outcomes measure.&#xD;
&#xD;
      The non-diabetic female with PCOS offers a unique model to study the relationship between&#xD;
      insulin resistance and adiposity. Women with PCOS demonstrate abnormal body composition&#xD;
      characterized by a greater percent body fat, body fat mass, and increased ratio of fat to&#xD;
      lean mass (F/L ratio). Studies using dual-energy X-ray absorptiometry (DEXA) methodology&#xD;
      report a higher degree of metabolic dysfunction in patients with PCOS which appears be&#xD;
      directly associated with their higher F/L ratio. Given that monotherapy and combined therapy&#xD;
      with exenatide once weekly (EQW),and dapagliflozin (DAPA) along with DAPA/ metformin XR&#xD;
      therapy are associated with weight loss introduces a confounder to the current study since it&#xD;
      prevents distinguishing direct effects of the compounds on β-cell function vs. effects due to&#xD;
      reduced adiposity. To control for loss of body mass and provide appropriate intervention in&#xD;
      the remaining study arm we propose the use of a comparator weight loss drug alone,&#xD;
      combination phentermine (PHEN)/topiramate (TPM) extended release (ER). To avoid the&#xD;
      confounding relationship of body fat and insulin resistance, we will enroll only obese&#xD;
      non-diabetic women with PCOS. All patients will receive diet and lifestyle counselling,&#xD;
      including advice on exercise, according to usual clinical routine commencing during the&#xD;
      lead-in period and continuing throughout the study We propose a randomized, single-blind,&#xD;
      parallel 5 treatment group 24-week trial designed to directly compare the therapeutic effects&#xD;
      of exenatide once weekly (EQW), dapagliflozin (DAPA), EQW plus DAPA, combined DAPA/metformin&#xD;
      ER and the weight loss medication, phentermine/topiramate extended release (PHEN/TPM ER) on&#xD;
      metabolic and endocrinological parameters in obese non-diabetic women with PCOS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 22, 2016</start_date>
  <completion_date type="Actual">October 9, 2020</completion_date>
  <primary_completion_date type="Actual">July 22, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oral Disposition (Insulin Sensitivity-insulin Secretion) Index</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>An estimation of β-cell compensatory function, the insulin secretion-sensitivity index (IS-SI) will be derived by applying the concept of the oral disposition index to measurements obtained during the 2-h OGTT and calculated as the index of insulin secretion factored by insulin sensitivity (ΔINS/ΔPG 30 x Matsuda SIOGTT) from the OGTT. A higher score shows improved pancreatic insulin responsiveness relative to resistance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Body Weight</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment effect on body weight at 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment efficacy in reducing body mass at 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Body Weight</measure>
    <time_frame>Change from baseline (time 0) to study end (24 weeks)</time_frame>
    <description>Treatment effect on change in percent body weight from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Adiposity (Waist Circumference)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment effect on loss of central adiposity after 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist-to-Hip Ratio (WHR)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment impact on central adiposity after 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist-to-Height Ratio (WHtR)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment impact on WHtR which is a measure of central adiposity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Fat Mass (kg) Evaluated by DEXA</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment impact on total fat mass by DEXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Fat (%) by DEXA</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment impact on percent total body fat by DEXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Android-Gynoid Ratio (AGR) as Determined by DEXA</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>treatment impact on measure of central adiposity as determined by android/gynoid ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trunk/Leg Fat Ratio by DEXA</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment impact on trunk/limb ratio (measure of central adiposity) by DEXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Glucose</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment impact on fasting concentration of glucose in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OGTT Mean Blood Glucose (MBG)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment effect on MBG measured during the oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Insulin Sensitivity (HOMA-IR)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment effect on the ratio HOMA-IR which is insulin resistance measure derived from fasting blood glucose and insulin and is calculated by insulin (mU/ml)*glucose (mmol/L)/22,5. The higher thenumber the more insulin resistant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matsuda Sensitivity Index Derived From the OGTT(SI OGTT)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>The SI IOGTT is a measure of peripheral insulin sensitivity derived from the values of Insulin (microunits per milliliter) and Glucose (milligrams per deciliter) obtained from the OGTT and the corresponding fasting values. SI (OGTT) = 10,000/ [(G fasting x I fasting) x (G OGTTmean x I OGTTmean)], where fasting glucose and insulin data are taken from time 0 of the OGTT and mean data represent the average glucose and insulin values obtained during the entire OGTT. The square root is used to correct for nonlinear distribution of insulin, and 10,000 is a scaling factor in the equation. The higher value, the more sensitive to insulin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected First Phase Insulin Secretion (IGI/HOMA-IR)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment effect on insulin secretion from 0 to 30 minutes after glucose load corrected for by fasting insulin sensitivity. A higher score shows improved first phase insulin secretion in response to glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol Levels</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment effect on blood concentrations of total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride (TRG) Levels</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment effect on blood concentrations of triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Testosterone Concentrations</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment effect on blood concentrations of total testosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dehydroepiandrosterone Sulfate (DHEA-S) Levels</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment effect on blood concentrations of DHEA-S</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Androgen Index (FAI)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment effect on FAI calculated from total testosterone divided by sex hormone binding globulin (SHBG) levels. A higher score indicates a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure (SBP)</measure>
    <time_frame>24 weeks treatment</time_frame>
    <description>Treatment effect on SBP after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure (DBP)</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Treatment effect on DBP after 24 weeks</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Exenatide once weekly (EQW )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin (DAPA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DAPA-10 mg oral pill once daily in am for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EQW plus DAPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin plus Glucophage (MET ER)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phentermine /Topiramate (PHEN/ TPM) ER</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide once weekly (EQW )</intervention_name>
    <description>2 mg SC injection every 7 days</description>
    <arm_group_label>Exenatide once weekly (EQW )</arm_group_label>
    <other_name>• Bydureon</other_name>
    <other_name>• Long acting glucagon like peptide 1 (GLP1) agonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin (DAPA)</intervention_name>
    <description>One pill (10 mg) by mouth daily (QD) in am</description>
    <arm_group_label>Dapagliflozin (DAPA)</arm_group_label>
    <other_name>• Farxiga</other_name>
    <other_name>• SGLT2 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EQW plus DAPA</intervention_name>
    <description>2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
    <arm_group_label>EQW plus DAPA</arm_group_label>
    <other_name>Bydureon plus Farxiga</other_name>
    <other_name>Long acting GLP1 agonist plus SGLT2 inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin plus Glucophage (MET ER)</intervention_name>
    <description>DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
    <arm_group_label>Dapagliflozin plus Glucophage (MET ER)</arm_group_label>
    <other_name>Xigduo</other_name>
    <other_name>•Combination SGLT2 inhibitor and metformin ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentermine /Topiramate (PHEN/ TPM) ER</intervention_name>
    <description>PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
    <arm_group_label>Phentermine /Topiramate (PHEN/ TPM) ER</arm_group_label>
    <other_name>Qsymia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Non-diabetic women (18-45 years)&#xD;
&#xD;
          2. PCOS- NIH criteria hyperandrogenism and irregular menses&#xD;
&#xD;
          3. Obese class I, II, and III (BMI &gt;30&lt;45)&#xD;
&#xD;
          4. Willing to use effective contraception consistently during therapy which is defined&#xD;
             as:&#xD;
&#xD;
               1. an intrauterine device, tubal sterilization, or male partner vasectomy, or&#xD;
&#xD;
               2. combination of two barrier methods with one being male condom.&#xD;
&#xD;
          5. Written consent for participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of significant systemic disease, heart problems including congestive heart&#xD;
             failure, unstable angina or acute myocardial infarction, current infectious liver&#xD;
             disease, acute stroke or transient ischemic attacks, history of pancreatitis, or&#xD;
             diabetes mellitus (Type 1 or 2)&#xD;
&#xD;
          2. Any hepatic diseases in the past (infectious liver disease, viral hepatitis, toxic&#xD;
             hepatic damage, jaundice of unknown etiology) or severe hepatic insufficiency and/or&#xD;
             significant abnormal liver function tests defined as aspartate aminotransferase (AST)&#xD;
             &gt;3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) &gt;3x ULN&#xD;
&#xD;
          3. Renal impairment (e.g., serum creatinine levels ≥1.4 mg/dL for women, or estimated&#xD;
             glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m2) or history of unstable or&#xD;
             rapidly progressing renal disease or end stage renal disease. Patients with a history&#xD;
             of nephrolithiasis are also excluded due to increased association with kidney stone&#xD;
             formation.&#xD;
&#xD;
          4. Uncontrolled thyroid disease (documented normal TSH), Cushing's syndrome, congenital&#xD;
             adrenal hyperplasia or hyperprolactinemia&#xD;
&#xD;
          5. Significantly elevated triglyceride levels (fasting triglyceride &gt; 400 mg/dL)&#xD;
&#xD;
          6. Untreated or poorly controlled hypertension (sitting blood pressure &gt; 160/95 mm Hg)&#xD;
&#xD;
          7. Use of hormonal medications, lipid-lowering (statins, etc.), anti-obesity drugs or&#xD;
             weight loss medications (prescription or OTC) and medications known to exacerbate&#xD;
             glucose tolerance (such as isotretinoin, hormonal contraceptives,&#xD;
             gonadotropin-releasing hormone agonists, glucocorticoids, anabolic steroids, C-19&#xD;
             progestins) stopped for at least 8 weeks. Use of anti-androgens that act peripherally&#xD;
             to reduce hirsutism such as 5-alpha reductase inhibitors (finasteride, spironolactone,&#xD;
             flutamide) stopped for at least 4 weeks&#xD;
&#xD;
          8. Prior history of a malignant disease requiring chemotherapy&#xD;
&#xD;
          9. Patients at risk for volume depletion due to co-existing conditions or concomitant&#xD;
             medications, such as loop diuretics should have careful monitoring of their volume&#xD;
             status&#xD;
&#xD;
         10. History of unexplained microscopic or gross hematuria, or microscopic hematuria at&#xD;
             visit 1, confirmed by a follow-up sample at next scheduled visit.&#xD;
&#xD;
         11. Presence of hypersensitivity to dapagliflozin or other SGLT2 inhibitors (e.g.&#xD;
             anaphylaxis, angioedema, exfoliative skin conditions&#xD;
&#xD;
         12. Known hypersensitivity or contraindications to use GLP1 receptor agonists (exenatide,&#xD;
             liraglutide)&#xD;
&#xD;
         13. Use of metformin, thiazolidinediones, GLP-1 receptor agonists, dipeptidyl peptidase 4&#xD;
             (DPP-4) inhibitors, SGLT2 inhibitors stopped for at least 4 weeks.&#xD;
&#xD;
         14. Prior use of medication to treat diabetes except gestational diabetes&#xD;
&#xD;
         15. Eating disorders (anorexia, bulimia) or gastrointestinal disorders&#xD;
&#xD;
         16. Suspected pregnancy (documented negative serum pregnancy test), desiring pregnancy in&#xD;
             next 6 months, breastfeeding, or known pregnancy in last 2 months&#xD;
&#xD;
         17. Active or prior history of substance abuse (smoke or tobacco use within past 3 years)&#xD;
             or significant intake of alcohol&#xD;
&#xD;
         18. Having a history of bariatric surgery&#xD;
&#xD;
         19. Patient not willing to use two barrier method contraception during study period&#xD;
             (unless sterilized or have an IUD)&#xD;
&#xD;
         20. Patients with glaucoma or history of increased intraocular pressure, or use of any&#xD;
             medications to treat increased intraocular pressure&#xD;
&#xD;
         21. Debilitating psychiatric disorder such as psychosis or neurological condition that&#xD;
             might confound outcome variables. Patients with a history of bipolar disorder or&#xD;
             psychosis, greater than one lifetime, episode of major depression, current depression&#xD;
             of moderate or greater severity (PHQ-9score of 10 or more), presence or history of&#xD;
             suicidal behavior or ideation with some intent to act on it, or antidepressant use&#xD;
             that has not been stable for at least 3 months will also be excluded.&#xD;
&#xD;
         22. Inability or refusal to comply with protocol&#xD;
&#xD;
         23. Current participation or participation in an experimental drug study in previous three&#xD;
             months&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Elkind-Hirsch, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Woman's Hospital, Louisiana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Drake Bellanger, MD</last_name>
    <role>Study Director</role>
    <affiliation>Woman's Hospital, Louisiana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Woman's Hospital</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2015</study_first_posted>
  <results_first_submitted>December 8, 2020</results_first_submitted>
  <results_first_submitted_qc>January 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2021</results_first_posted>
  <last_update_submitted>January 9, 2021</last_update_submitted>
  <last_update_submitted_qc>January 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Woman's</investigator_affiliation>
    <investigator_full_name>Karen Elkind-Hirsch</investigator_full_name>
    <investigator_title>Director of Research</investigator_title>
  </responsible_party>
  <keyword>PCOS</keyword>
  <keyword>GLP1 agonists</keyword>
  <keyword>SGLT2 inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
    <mesh_term>Phentermine</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual data will only be shared with participant</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02635386/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 29, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT02635386/Prot_SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>130 consented and 11 did not meet criteria and not randomized</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Exenatide Once Weekly (EQW )</title>
          <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
        </group>
        <group group_id="P2">
          <title>Dapagliflozin (DAPA)</title>
          <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
        </group>
        <group group_id="P3">
          <title>EQW Plus DAPA</title>
          <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
        </group>
        <group group_id="P4">
          <title>Dapagliflozin Plus Glucophage (MET ER)</title>
          <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
        </group>
        <group group_id="P5">
          <title>Phentermine /Topiramate (PHEN/ TRP) ER</title>
          <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TRP) ER: PHEN 3.75/TRP ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TRP ER 46mg- 1 pill by mouth once daily in am</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved Out of State</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>side effects</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>needed other major surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other medical problems not drug related</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants were started on medicine</population>
      <group_list>
        <group group_id="B1">
          <title>Exenatide Once Weekly (EQW )</title>
          <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
        </group>
        <group group_id="B2">
          <title>Dapagliflozin (DAPA)</title>
          <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
        </group>
        <group group_id="B3">
          <title>EQW Plus DAPA</title>
          <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
        </group>
        <group group_id="B4">
          <title>Dapagliflozin Plus Glucophage (MET ER)</title>
          <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
        </group>
        <group group_id="B5">
          <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
          <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="25"/>
            <count group_id="B6" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.6" spread="5.1"/>
                    <measurement group_id="B2" value="29.2" spread="6.3"/>
                    <measurement group_id="B3" value="31.4" spread="6.3"/>
                    <measurement group_id="B4" value="29.6" spread="7.0"/>
                    <measurement group_id="B5" value="29" spread="5.6"/>
                    <measurement group_id="B6" value="29.9" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <description>all patients were obese to enter trial</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.6" spread="5.1"/>
                    <measurement group_id="B2" value="38" spread="5.1"/>
                    <measurement group_id="B3" value="39.9" spread="4.2"/>
                    <measurement group_id="B4" value="37.6" spread="4.5"/>
                    <measurement group_id="B5" value="38.4" spread="4.4"/>
                    <measurement group_id="B6" value="38.3" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Oral Disposition (Insulin Sensitivity-insulin Secretion) Index</title>
        <description>An estimation of β-cell compensatory function, the insulin secretion-sensitivity index (IS-SI) will be derived by applying the concept of the oral disposition index to measurements obtained during the 2-h OGTT and calculated as the index of insulin secretion factored by insulin sensitivity (ΔINS/ΔPG 30 x Matsuda SIOGTT) from the OGTT. A higher score shows improved pancreatic insulin responsiveness relative to resistance.</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Disposition (Insulin Sensitivity-insulin Secretion) Index</title>
          <description>An estimation of β-cell compensatory function, the insulin secretion-sensitivity index (IS-SI) will be derived by applying the concept of the oral disposition index to measurements obtained during the 2-h OGTT and calculated as the index of insulin secretion factored by insulin sensitivity (ΔINS/ΔPG 30 x Matsuda SIOGTT) from the OGTT. A higher score shows improved pancreatic insulin responsiveness relative to resistance.</description>
          <units>index score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="471" spread="83"/>
                    <measurement group_id="O2" value="311" spread="90"/>
                    <measurement group_id="O3" value="503" spread="80"/>
                    <measurement group_id="O4" value="395" spread="85"/>
                    <measurement group_id="O5" value="545" spread="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.02</p_value>
            <method>ANOVA</method>
            <method_desc>nested repeated measure</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Body Weight</title>
        <description>Treatment effect on body weight at 24 weeks of treatment</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Body Weight</title>
          <description>Treatment effect on body weight at 24 weeks of treatment</description>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.4" spread="3.7"/>
                    <measurement group_id="O2" value="102.6" spread="4"/>
                    <measurement group_id="O3" value="99" spread="3.7"/>
                    <measurement group_id="O4" value="101.2" spread="3.8"/>
                    <measurement group_id="O5" value="97" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index (BMI)</title>
        <description>Treatment efficacy in reducing body mass at 24 weeks of treatment</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Treatment efficacy in reducing body mass at 24 weeks of treatment</description>
          <units>kilogram/meter squared</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" spread="1.1"/>
                    <measurement group_id="O2" value="37.4" spread="1.2"/>
                    <measurement group_id="O3" value="36.7" spread="1.1"/>
                    <measurement group_id="O4" value="37" spread="1.2"/>
                    <measurement group_id="O5" value="35.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent Body Weight</title>
        <description>Treatment effect on change in percent body weight from baseline</description>
        <time_frame>Change from baseline (time 0) to study end (24 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Body Weight</title>
          <description>Treatment effect on change in percent body weight from baseline</description>
          <units>percentage change in body weight</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="0.8"/>
                    <measurement group_id="O2" value="1.5" spread="1.4"/>
                    <measurement group_id="O3" value="6.9" spread="0.9"/>
                    <measurement group_id="O4" value="1.7" spread="1.0"/>
                    <measurement group_id="O5" value="8.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>One way ANOVA with Bonferroni test to compare differences between groups if significant</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>one way with Bonferroni contrast</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Central Adiposity (Waist Circumference)</title>
        <description>Treatment effect on loss of central adiposity after 24 weeks</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Central Adiposity (Waist Circumference)</title>
          <description>Treatment effect on loss of central adiposity after 24 weeks</description>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" spread="3"/>
                    <measurement group_id="O2" value="101" spread="3.2"/>
                    <measurement group_id="O3" value="106" spread="3"/>
                    <measurement group_id="O4" value="101.3" spread="3"/>
                    <measurement group_id="O5" value="97" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist-to-Hip Ratio (WHR)</title>
        <description>Treatment impact on central adiposity after 24 weeks</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Waist-to-Hip Ratio (WHR)</title>
          <description>Treatment impact on central adiposity after 24 weeks</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".83" spread=".016"/>
                    <measurement group_id="O2" value=".79" spread=".017"/>
                    <measurement group_id="O3" value=".86" spread=".016"/>
                    <measurement group_id="O4" value=".83" spread=".016"/>
                    <measurement group_id="O5" value=".81" spread=".018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measure design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist-to-Height Ratio (WHtR)</title>
        <description>Treatment impact on WHtR which is a measure of central adiposity</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Waist-to-Height Ratio (WHtR)</title>
          <description>Treatment impact on WHtR which is a measure of central adiposity</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".64" spread=".018"/>
                    <measurement group_id="O2" value=".61" spread=".02"/>
                    <measurement group_id="O3" value=".65" spread=".018"/>
                    <measurement group_id="O4" value=".61" spread=".019"/>
                    <measurement group_id="O5" value=".59" spread=".021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Fat Mass (kg) Evaluated by DEXA</title>
        <description>Treatment impact on total fat mass by DEXA</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPMER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Total Fat Mass (kg) Evaluated by DEXA</title>
          <description>Treatment impact on total fat mass by DEXA</description>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" spread="2.4"/>
                    <measurement group_id="O2" value="47.8" spread="2.6"/>
                    <measurement group_id="O3" value="45.9" spread="2.4"/>
                    <measurement group_id="O4" value="48" spread="2.5"/>
                    <measurement group_id="O5" value="44.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body Fat (%) by DEXA</title>
        <description>Treatment impact on percent total body fat by DEXA</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPMER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Fat (%) by DEXA</title>
          <description>Treatment impact on percent total body fat by DEXA</description>
          <units>percent fat mass</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1" spread="1.1"/>
                    <measurement group_id="O2" value="46.4" spread="1.2"/>
                    <measurement group_id="O3" value="45.8" spread="1.1"/>
                    <measurement group_id="O4" value="46.1" spread="1.1"/>
                    <measurement group_id="O5" value="45.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Android-Gynoid Ratio (AGR) as Determined by DEXA</title>
        <description>treatment impact on measure of central adiposity as determined by android/gynoid ratio</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Android-Gynoid Ratio (AGR) as Determined by DEXA</title>
          <description>treatment impact on measure of central adiposity as determined by android/gynoid ratio</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread=".024"/>
                    <measurement group_id="O2" value="1.02" spread=".03"/>
                    <measurement group_id="O3" value="1.04" spread=".02"/>
                    <measurement group_id="O4" value="1.04" spread=".03"/>
                    <measurement group_id="O5" value="1.03" spread=".03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trunk/Leg Fat Ratio by DEXA</title>
        <description>Treatment impact on trunk/limb ratio (measure of central adiposity) by DEXA</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Trunk/Leg Fat Ratio by DEXA</title>
          <description>Treatment impact on trunk/limb ratio (measure of central adiposity) by DEXA</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread=".045"/>
                    <measurement group_id="O2" value=".95" spread=".048"/>
                    <measurement group_id="O3" value=".93" spread=".045"/>
                    <measurement group_id="O4" value=".98" spread=".047"/>
                    <measurement group_id="O5" value=".99" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.035</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Blood Glucose</title>
        <description>Treatment impact on fasting concentration of glucose in the blood</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Blood Glucose</title>
          <description>Treatment impact on fasting concentration of glucose in the blood</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" spread="1.9"/>
                    <measurement group_id="O2" value="93" spread="2.1"/>
                    <measurement group_id="O3" value="86.5" spread="1.9"/>
                    <measurement group_id="O4" value="89" spread="2.0"/>
                    <measurement group_id="O5" value="91.4" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OGTT Mean Blood Glucose (MBG)</title>
        <description>Treatment effect on MBG measured during the oral glucose tolerance test</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>OGTT Mean Blood Glucose (MBG)</title>
          <description>Treatment effect on MBG measured during the oral glucose tolerance test</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118" spread="4.8"/>
                    <measurement group_id="O2" value="126.4" spread="5.2"/>
                    <measurement group_id="O3" value="112" spread="4.8"/>
                    <measurement group_id="O4" value="119" spread="4.9"/>
                    <measurement group_id="O5" value="113" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.02</p_value>
            <method>ANOVA</method>
            <method_desc>nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Insulin Sensitivity (HOMA-IR)</title>
        <description>Treatment effect on the ratio HOMA-IR which is insulin resistance measure derived from fasting blood glucose and insulin and is calculated by insulin (mU/ml)*glucose (mmol/L)/22,5. The higher thenumber the more insulin resistant.</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Insulin Sensitivity (HOMA-IR)</title>
          <description>Treatment effect on the ratio HOMA-IR which is insulin resistance measure derived from fasting blood glucose and insulin and is calculated by insulin (mU/ml)*glucose (mmol/L)/22,5. The higher thenumber the more insulin resistant.</description>
          <units>index score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="0.55"/>
                    <measurement group_id="O2" value="3.6" spread="0.6"/>
                    <measurement group_id="O3" value="2.6" spread="0.55"/>
                    <measurement group_id="O4" value="3.3" spread="0.57"/>
                    <measurement group_id="O5" value="3.4" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.035</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Matsuda Sensitivity Index Derived From the OGTT(SI OGTT)</title>
        <description>The SI IOGTT is a measure of peripheral insulin sensitivity derived from the values of Insulin (microunits per milliliter) and Glucose (milligrams per deciliter) obtained from the OGTT and the corresponding fasting values. SI (OGTT) = 10,000/ [(G fasting x I fasting) x (G OGTTmean x I OGTTmean)], where fasting glucose and insulin data are taken from time 0 of the OGTT and mean data represent the average glucose and insulin values obtained during the entire OGTT. The square root is used to correct for nonlinear distribution of insulin, and 10,000 is a scaling factor in the equation. The higher value, the more sensitive to insulin.</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Matsuda Sensitivity Index Derived From the OGTT(SI OGTT)</title>
          <description>The SI IOGTT is a measure of peripheral insulin sensitivity derived from the values of Insulin (microunits per milliliter) and Glucose (milligrams per deciliter) obtained from the OGTT and the corresponding fasting values. SI (OGTT) = 10,000/ [(G fasting x I fasting) x (G OGTTmean x I OGTTmean)], where fasting glucose and insulin data are taken from time 0 of the OGTT and mean data represent the average glucose and insulin values obtained during the entire OGTT. The square root is used to correct for nonlinear distribution of insulin, and 10,000 is a scaling factor in the equation. The higher value, the more sensitive to insulin.</description>
          <units>index score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="0.6"/>
                    <measurement group_id="O2" value="3.6" spread="0.7"/>
                    <measurement group_id="O3" value="3.9" spread="0.6"/>
                    <measurement group_id="O4" value="4.8" spread="0.6"/>
                    <measurement group_id="O5" value="4.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corrected First Phase Insulin Secretion (IGI/HOMA-IR)</title>
        <description>Treatment effect on insulin secretion from 0 to 30 minutes after glucose load corrected for by fasting insulin sensitivity. A higher score shows improved first phase insulin secretion in response to glucose</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Corrected First Phase Insulin Secretion (IGI/HOMA-IR)</title>
          <description>Treatment effect on insulin secretion from 0 to 30 minutes after glucose load corrected for by fasting insulin sensitivity. A higher score shows improved first phase insulin secretion in response to glucose</description>
          <units>index score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="0.2"/>
                    <measurement group_id="O2" value="0.6" spread="0.21"/>
                    <measurement group_id="O3" value="0.91" spread="0.2"/>
                    <measurement group_id="O4" value="0.7" spread="0.2"/>
                    <measurement group_id="O5" value="1.1" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.04</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol Levels</title>
        <description>Treatment effect on blood concentrations of total cholesterol</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol Levels</title>
          <description>Treatment effect on blood concentrations of total cholesterol</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189" spread="10"/>
                    <measurement group_id="O2" value="186" spread="11"/>
                    <measurement group_id="O3" value="185" spread="10"/>
                    <measurement group_id="O4" value="192" spread="11"/>
                    <measurement group_id="O5" value="178" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglyceride (TRG) Levels</title>
        <description>Treatment effect on blood concentrations of triglycerides</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride (TRG) Levels</title>
          <description>Treatment effect on blood concentrations of triglycerides</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" spread="12"/>
                    <measurement group_id="O2" value="132" spread="13"/>
                    <measurement group_id="O3" value="112" spread="12"/>
                    <measurement group_id="O4" value="105" spread="12"/>
                    <measurement group_id="O5" value="110" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.04</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Testosterone Concentrations</title>
        <description>Treatment effect on blood concentrations of total testosterone</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Total Testosterone Concentrations</title>
          <description>Treatment effect on blood concentrations of total testosterone</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" spread="4"/>
                    <measurement group_id="O2" value="35" spread="4.4"/>
                    <measurement group_id="O3" value="42.6" spread="4"/>
                    <measurement group_id="O4" value="39.5" spread="4.1"/>
                    <measurement group_id="O5" value="45.5" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dehydroepiandrosterone Sulfate (DHEA-S) Levels</title>
        <description>Treatment effect on blood concentrations of DHEA-S</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Dehydroepiandrosterone Sulfate (DHEA-S) Levels</title>
          <description>Treatment effect on blood concentrations of DHEA-S</description>
          <units>mcg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165" spread="22"/>
                    <measurement group_id="O2" value="187" spread="24"/>
                    <measurement group_id="O3" value="169" spread="22"/>
                    <measurement group_id="O4" value="189" spread="23"/>
                    <measurement group_id="O5" value="201" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free Androgen Index (FAI)</title>
        <description>Treatment effect on FAI calculated from total testosterone divided by sex hormone binding globulin (SHBG) levels. A higher score indicates a worse outcome.</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Free Androgen Index (FAI)</title>
          <description>Treatment effect on FAI calculated from total testosterone divided by sex hormone binding globulin (SHBG) levels. A higher score indicates a worse outcome.</description>
          <units>index score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="0.72"/>
                    <measurement group_id="O2" value="4.7" spread="0.8"/>
                    <measurement group_id="O3" value="5.2" spread="0.73"/>
                    <measurement group_id="O4" value="5.7" spread="0.74"/>
                    <measurement group_id="O5" value="5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure (SBP)</title>
        <description>Treatment effect on SBP after 24 weeks of treatment</description>
        <time_frame>24 weeks treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure (SBP)</title>
          <description>Treatment effect on SBP after 24 weeks of treatment</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.6" spread="1.9"/>
                    <measurement group_id="O2" value="123" spread="2.0"/>
                    <measurement group_id="O3" value="122" spread="1.9"/>
                    <measurement group_id="O4" value="128" spread="1.8"/>
                    <measurement group_id="O5" value="124" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.035</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure (DBP)</title>
        <description>Treatment effect on DBP after 24 weeks</description>
        <time_frame>24 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exenatide Once Weekly (EQW )</title>
            <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin (DAPA)</title>
            <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
          </group>
          <group group_id="O3">
            <title>EQW Plus DAPA</title>
            <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
          </group>
          <group group_id="O4">
            <title>Dapagliflozin Plus Glucophage (MET ER)</title>
            <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
          </group>
          <group group_id="O5">
            <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
            <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure (DBP)</title>
          <description>Treatment effect on DBP after 24 weeks</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" spread="1.7"/>
                    <measurement group_id="O2" value="79.8" spread="1.9"/>
                    <measurement group_id="O3" value="76" spread="1.7"/>
                    <measurement group_id="O4" value="82" spread="1.8"/>
                    <measurement group_id="O5" value="83.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Repeated Measure general linear model (SS/Drug treatments by visits) including arm of drug treatment as between subjects effect and visit (baseline and post 22-24 weeks treatment) as within subject effect</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.035</p_value>
            <method>ANOVA</method>
            <method_desc>Nested repeated measures design</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Exenatide Once Weekly (EQW )</title>
          <description>EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks&#xD;
Exenatide once weekly (EQW ): 2 mg SC injection every 7 days</description>
        </group>
        <group group_id="E2">
          <title>Dapagliflozin (DAPA)</title>
          <description>DAPA-10 mg oral pill once daily in am for 24 weeks&#xD;
Dapagliflozin (DAPA): One pill (10 mg) by mouth daily (QD) in am</description>
        </group>
        <group group_id="E3">
          <title>EQW Plus DAPA</title>
          <description>EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks&#xD;
EQW plus DAPA: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am</description>
        </group>
        <group group_id="E4">
          <title>Dapagliflozin Plus Glucophage (MET ER)</title>
          <description>Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks&#xD;
Dapagliflozin plus Glucophage (MET ER): DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose</description>
        </group>
        <group group_id="E5">
          <title>Phentermine /Topiramate (PHEN/ TPM) ER</title>
          <description>Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks&#xD;
Phentermine /Topiramate (PHEN/ TPM) ER: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <description>pregnancy was considered a serious AE and reported to the IRB, FDA and company</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Rapid heartbeat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and upset stomach</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Lightheaded</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Yeast infection or urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Kidney Stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Prolonged menstrual cycle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stuffy Nose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One limitation of this study is the lack of a placebo only arm. As we were interested in the effects of different treatment regimens for obese women with PCOS, this study was designed to provide all patients with drug therapy. Limitations of the present study further include the absence of gold-standard measures of insulin sensitivity ; instead we used the OGTT using established surrogate measures.. Last, serial assessments were over only 24 weeks of treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Karen Elkind-Hirsch</name_or_title>
      <organization>Woman's Hospital</organization>
      <phone>2252315278</phone>
      <email>karen.elkind-hirsch@womans.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

